Barclays analyst Carter Gould lowered the firm’s price target on Biogen to $302 from $307 and keeps an Equal Weight rating on the shares. The company reported a "lackluster" Q1 print, but the set-up is intact into the "high-profile" Alzheimer’s catalysts, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- FDA approves Ionis Pharma/Biogen’s QALSODY as first treatment in ALS
- Biogen price target raised to $371 from $349 at Morgan Stanley
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen confirms FDA grants accelerated approval for Qalsody
- FDA approves Biogen’s Qalsody for ALS patients with SOD1 gene mutation